However, Iannone et al. support the hypothesis that inhibition of adenosine production in tumors or inhibition of A2aR is a promising strategy to increase the effectiveness of melanoma immunotherapy, because they have done a lot of experiments proving that adenosine can limit the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model [43]. This evidence concerns the gene ADORA2A and melanoma.